Tocilizumab

JC viraemia: case report

In a case study involving 25 patients conducted between January 2013 and November 2018, one patient [age and sex not stated] was described, who developed JC viraemia during treatment with tocilizumab for chronic Antibody Mediated Rejection (cAMBR) post renal transplantation [route, dosage and duration of treatment to reaction onset not stated]. Subsequently, the patient’s treatment with tocilizumab was discontinued [outcome not stated].

Pearl M, et al. Long term safety and efficacy of tocilizumab (anti-IL6R, TCZ) therapy in the treatment of refractory chronic antibody mediated rejection (CABMR) in 25 pediatric renal transplant recipients. American Journal of Transplantation 21 (Suppl): 323, Jun 2021. Available from: URL: http://doi.org/10.1111/ajt.16847
[abstract]